Overview

Anecortave Acetate Risk-Reduction Trial (AART)

Status:
Terminated

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of non-exudative (dry) age-related macular degeneration in patients who are at risk for progressing to exudative (wet) age-related macular degeneration.

Phase:

Phase 3

Details

Lead Sponsor:

Alcon Research

Treatments:

Anecortave
Hydrocortisone